US Bioservices Selected by Rigel Pharmaceuticals, Inc. to Dispense TAVALISSE (fostamatinib disodium hexahydrate) Tablets

US Bioservices, a specialty pharmacy that is a part of
AmerisourceBergen, announced today it has been selected by Rigel
Pharmaceuticals to dispense TAVALISSE™ (fostamatinib disodium
hexahydrate) Tablets. TAVALISSE™ was approved by the U.S. Food
and Drug Administration on April 17, 2018 for the treatment of adult
patients with chronic immune thrombocytopenia (ITP) who have had an
insufficient response to a previous treatment. ITP is a rare blood
disorder in which the immune system attacks and destroys platelets in
the blood.

ITP impacts approximately 65,000 adult patients in the U.S. The disorder
can be characterized by excessive bruising and bleeding due to
abnormally low platelet counts. Many adult patients with ITP develop the
chronic form of the disease that requires more specialized disease
management and continued follow-up care with a hematologist. Rigel
Pharmaceuticals’ fostamatinib ITP program was developed to treat chronic
ITP, targeting an underlying autoimmune cause of the disease through
inhibiting the SYK pathway.

“Adult patients with rare and orphan diseases like chronic ITP often
require highly targeted and specialized therapy. This is especially true
for chronic ITP patients who had an inadequate response to previous
treatment, requiring specialized care,” said Kelly Ratliff, President of
US Bioservices. “US Bioservices’ unmatched experience in rare disease,
hematology and oncology allows us to apply a unique,
clinically-coordinated approach that specifically supports the needs of
the smallest patient populations in their communities.”

US Bioservices’ multidisciplinary teams are organized to develop
long-standing, collaborative relationships with hematologists and
oncologists in order to deliver more integrated care for patients and
caregivers. In addition to US Bioservices, AmerisourceBergen companies –
ASD Healthcare, Oncology Supply and ION Solutions – will respectively
support specialty distribution to health systems and hematology and
community oncology practices for the launch of TAVALISSE™. Whether a
patient presents for care in a health system or community prescriber’s
office, patients will be able to fill their prescriptions at their
preferred point of care. This concerted approach will strategically and
geographically increase the accessibility of TAVALISSE™ for patients and
allow for a seamless transition to US Bioservices pharmacy dispensing.

TAVALISSE™ is a limited distribution medication that is available from
select specialty pharmacies. Physicians may submit prescriptions to US
Bioservices via phone (855.751.7953), fax (888.418.7246),
ePrescribe or the MyPathpoint
Prescriber Portal.

Important Safety Information

Warnings and Precautions

Drug Interactions

Adverse Reactions

For more information including full prescribing information and
important safety information, please visit www.TAVALISSE.com

1 http://ir.rigel.com/phoenix.zhtml?c=120936&p=irol-newsArticle&ID=2343080
. Accessed June 1, 2018.

About AmerisourceBergen

AmerisourceBergen provides pharmaceutical products, value-driving
services and business solutions that improve access to care. Tens of
thousands of healthcare providers, veterinary practices and livestock
producers trust us as their partner in the pharmaceutical supply chain.
Global manufacturers depend on us for services that drive commercial
success for their products. Through our daily work—and powered by our
21,000 associates—we are united in our responsibility to create
healthier futures. AmerisourceBergen is ranked #12 on the Fortune 500,
with more than $150 billion in annual revenue. The company is
headquartered in Valley Forge, PA and has a presence in 50+ countries.
Learn more at amerisourcebergen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180618005185/en/